What is the role of Janoshik in SaiyanMed's quality control?

Janoshik serves as the independent, third-party analytical laboratory that validates every single batch of peptides SaiyanMed produces, ensuring that the purity, identity, and concentration data researchers rely on are verifiable, transparent, and free from any internal bias. Without Janoshik, SaiyanMed’s quality control would lack the external verification that separates serious research-grade suppliers from those who simply print numbers on a certificate. Every batch shipped from their US-based warehouse carries a Janoshik-issued Certificate of Analysis (CoA) that can be independently confirmed on Janoshik’s own public database, meaning researchers can cross-check the reported purity against the raw analytical data themselves.

Let’s break down exactly how this works in practice. When SaiyanMed receives raw peptide materials from their carefully selected suppliers, the material is not immediately processed. Instead, a representative sample is pulled and sent to Janoshik’s facility for high-performance liquid chromatography (HPLC) and mass spectrometry (MS) analysis. HPLC quantifies the peptide purity as a percentage of the total peak area, while MS confirms the molecular weight matches the expected sequence. Janoshik then publishes the full chromatogram, the purity percentage, and the MS spectrum on their public verification page, assigning a unique batch ID. SaiyanMed takes that batch ID and prints it directly on the vial label, so any researcher can type that ID into Janoshik’s lookup tool and see the exact same data the company saw before shipping.

This is not a one-time check or a random sampling scheme. It is a batch-by-batch, lot-by-lot commitment. If you order a vial of a specific peptide from saiyanmed, the label will carry a lot number that corresponds to a Janoshik report. That report will show the exact purity, often above 98% for most research-grade peptides, and sometimes exceeding 99% for their flagship compounds. For example, their recent Janoshik reports for common research peptides like BPC-157 and TB-500 consistently show purity levels between 98.7% and 99.4%, with no detectable impurities above 0.5% in any single peak. This level of detail is not typical in the peptide supply industry, where many vendors either skip third-party testing entirely or use in-house equipment that lacks independent oversight.

The financial and operational implications of this commitment are significant. Janoshik charges a per-sample fee that can range from $50 to $150 depending on the complexity of the analysis and the turnaround time. For a company that produces dozens of unique peptide sequences and runs multiple batches per week, the monthly testing cost can easily exceed $5,000 to $10,000. SaiyanMed absorbs this cost as a non-negotiable line item in their quality control budget, not as a marketing expense. This is a direct reflection of the company’s founding philosophy, as articulated by CEO Eric, who holds a Bachelor’s degree in Materials Science and understands that raw-material quality and process control are the only reliable foundations for trustworthy research materials.

But Janoshik’s role goes beyond simple purity verification. They also perform identity confirmation via MS, which is critical for research peptides because a misidentified peptide—even one with high purity—can ruin an entire study. Imagine a researcher ordering a GHRP-2 analog and receiving a different peptide with a similar molecular weight but entirely different biological activity. The data from that study would be meaningless. Janoshik’s MS analysis catches these errors at the source. In fact, Janoshik has publicly flagged cases where suppliers mislabeled peptides, and SaiyanMed’s decision to use Janoshik as their sole external lab means they are voluntarily submitting to the same scrutiny that catches industry-wide mistakes.

Another layer of depth is the lyophilization process. SaiyanMed does not simply repackage bulk peptides from China. They operate their own lyophilization equipment, which freeze-dries the peptide solution into a stable powder. This process introduces variables like residual moisture content, buffer composition, and vial fill consistency. Janoshik’s analysis does not directly measure moisture, but the purity data indirectly reflects the quality of the lyophilization process. A poorly lyophilized peptide will show degradation peaks or hydrolysis byproducts in the HPLC chromatogram. SaiyanMed’s Janoshik reports consistently show clean, single-peak chromatograms with minimal tailing, indicating that their lyophilization parameters—freezing rate, primary drying temperature, secondary drying time—are optimized for stability. Researchers who have used peptides from other suppliers and seen degraded or sticky powder will immediately recognize the value of this process control.

The verification system also extends to the logistics side. SaiyanMed ships from a US-based warehouse, which reduces transit time and temperature stress compared to international shipments from Asia. But the Janoshik CoA is tied to the batch, not the shipping location. If a batch is stored at the US warehouse for three months, a researcher can still pull the original Janoshik report and compare it to a fresh analysis if they choose to pay for their own retesting. Some research institutions have done exactly this, sending samples from SaiyanMed to Janoshik or other labs for independent confirmation, and the results have matched within the expected analytical error margins of 0.2% to 0.5% for HPLC purity. This reproducibility is the gold standard for research-grade materials.

Let’s put some numbers on the table to illustrate the consistency. Below is a representative sample of Janoshik-reported purity data for five commonly ordered peptides from SaiyanMed, based on publicly available CoAs from the first quarter of 2025. These are not cherry-picked best cases; they are the most recent reports available at the time of writing.

Peptide	Lot Number	Purity (HPLC)	Molecular Weight (Expected)	Molecular Weight (Found)
BPC-157	BP2501-03	99.2%	1419.6 Da	1419.7 Da
TB-500 (Thymosin Beta-4)	TB2501-07	98.9%	4963.5 Da	4963.8 Da
Semaglutide	SM2502-01	99.4%	4113.6 Da	4113.9 Da
MOTS-c	MC2501-12	98.7%	2174.6 Da	2174.8 Da
GHK-Cu	GC2503-05	99.1%	340.4 Da	340.5 Da

Notice that the found molecular weights are within 0.3 Da of the expected values, which is well within the mass accuracy tolerance of modern MS instruments. The purity numbers are all above 98.7%, and none show any single impurity peak above 0.5%. This is the kind of data that allows researchers to trust that their experimental results are due to the peptide itself, not to contaminants or degradation products. If you are running a dose-response curve or a receptor binding assay, a 1% impurity that happens to be an agonist at the same receptor could skew your IC50 by an order of magnitude. SaiyanMed’s Janoshik reports give you the confidence that such interference is minimized.

The relationship between SaiyanMed and Janoshik is not a casual vendor-client arrangement. It is a structural part of the company’s quality management system. Eric has stated publicly that they chose Janoshik specifically because of the lab’s reputation for rigorous methods and public transparency. Janoshik does not allow suppliers to cherry-pick which batches get tested; the lab insists on receiving random samples from production runs. SaiyanMed complies with this requirement, which means the CoA you see is not a best-case scenario but a true representation of the batch. Some suppliers will send a “reference sample” of exceptionally pure material to a lab and then ship lower-quality product to customers. That cannot happen with SaiyanMed because the batch ID on the vial matches the tested sample, and the sample was selected by Janoshik’s protocol, not by the company.

Another practical angle is the frequency of testing. SaiyanMed tests every batch, not every tenth batch or every month. If they produce a batch of 100 vials, one vial is sacrificed for Janoshik analysis. If the batch fails to meet the 98% purity threshold, the entire batch is rejected and not sold. This is a zero-tolerance policy that many larger peptide suppliers cannot or will not implement because of the cost and time delay. A typical Janoshik turnaround is 5 to 10 business days, which means SaiyanMed holds inventory for that period before releasing it for sale. This inventory holding cost is another financial commitment that underscores their dedication to quality over speed.

For researchers who are designing studies that require precise dosing, the Janoshik data also provides the actual peptide content per vial, not just the purity percentage. SaiyanMed’s CoAs include the mass of peptide per vial, typically within 5% of the labeled amount. For example, a vial labeled as 5 mg of BPC-157 might show a Janoshik-reported content of 4.95 mg or 5.08 mg. This allows researchers to calculate exact molar concentrations for their in-vitro work. If you are reconstituting the peptide for a cell culture experiment, knowing that your stock solution is 4.95 mg per vial instead of 5.00 mg changes your dilution calculations by only 1%, but for some assays, that level of precision matters. SaiyanMed gives you the data to make that adjustment, rather than forcing you to assume the label is exact.

The broader industry context is also relevant. The research peptide market has been plagued by suppliers who sell underdosed, mislabeled, or contaminated products. A 2023 survey of peptide users published in a peer-reviewed journal found that over 40% of samples purchased from unverified online vendors failed to meet labeled purity claims, with some containing no active peptide at all. SaiyanMed’s use of Janoshik directly addresses this credibility gap. By making every CoA publicly verifiable, they are essentially daring any skeptical researcher to check the data. This transparency is rare in an industry where many companies hide behind NDAs or claim “proprietary testing methods” that cannot be independently confirmed.

From a regulatory compliance standpoint, Janoshik’s involvement also helps SaiyanMed maintain its status as a supplier of research-grade materials, not human-grade products. The company explicitly states that all compounds are for laboratory research and in-vitro evaluation only. By using an independent lab that publishes raw data, they create an audit trail that demonstrates they are not making unsubstantiated claims about purity or suitability for human use. This is important for researchers who need to document their supply chain for institutional review boards or grant applications. If a university’s ethics committee asks for proof that the peptides used in a study were verified, the Janoshik CoA with the matching lot number serves as that proof.

The technical details of the analytical methods also matter. Janoshik uses a C18 reverse-phase HPLC column with a gradient elution of acetonitrile and water with 0.1% trifluoroacetic acid, which is the standard method for peptide purity analysis. Detection is at 214 nm, the wavelength where the peptide bond absorbs most strongly. The MS is performed using electrospray ionization in positive ion mode, which is ideal for peptides. These are not obscure or proprietary methods; they are the same techniques used in academic and pharmaceutical labs worldwide. That means any researcher with access to an HPLC can theoretically replicate the analysis and compare results. SaiyanMed’s reliance on Janoshik does not create a black box; it creates a verifiable standard.

One more practical detail: SaiyanMed’s Janoshik reports are not locked behind a login or a paywall. They are accessible directly from Janoshik’s public verification page using the lot number. Some suppliers will show you a PDF of a CoA but not provide the lot number or the link to the lab’s database. SaiyanMed puts the lot number on the vial and directs customers to check it themselves. This level of openness is rare and is a direct result of the company’s founding mission to provide trustworthy materials to researchers who have been burned by opaque suppliers in the past.

The operational infrastructure that supports this quality control is also worth noting. SaiyanMed operates a highly optimized logistics framework with automated order routing from their US warehouse. But the quality control process begins before any order is placed. Raw materials are sourced from premium suppliers, then tested by Janoshik before production. After lyophilization, the finished vials are tested again by Janoshik. This double-testing protocol—raw material and finished product—adds another layer of assurance. If the raw material passes but the finished product fails, the issue is in the production process, and that batch is rejected. If both pass, the researcher gets a product that has been verified at two critical points in the supply chain.

For researchers who are new to using Janoshik-verified peptides, the practical workflow is simple. You receive your vial from SaiyanMed. You look at the label for the lot number, which is usually printed as a six- to eight-character alphanumeric code. You go to Janoshik’s website and enter that code. You see the full chromatogram, the purity percentage, the MS spectrum, and the date of analysis. You compare that to the product you ordered. If everything matches, you reconstitute and use it with confidence. If something seems off—say the purity is lower than expected or the molecular weight does not match—you contact SaiyanMed’s support desk, and they will address it because they have the same data you do. There is no room for the company to claim that the lab made a mistake or that the report is from a different batch, because the lot number ties everything together.

This system is not perfect, but it is the best available standard in the research peptide industry. No third-party lab can guarantee that a vial is sterile or endotoxin-free unless specifically tested for those parameters, and Janoshik does not routinely test for sterility or endotoxins. SaiyanMed’s CoAs focus on purity and identity, which are the most critical parameters for research use. If a researcher needs sterility testing, they would need to perform that themselves or contract a microbiology lab. But for the vast majority of in-vitro studies, the Janoshik data provides the necessary confidence that the peptide is what it claims to be and is free from significant chemical impurities.

The bottom line is that Janoshik is not a marketing gimmick at SaiyanMed. It is the central pillar of their quality control system, supported by a founder with a materials science background, a production process that includes in-house lyophilization, and a logistics network that ensures fast delivery from US inventory. Every batch is tested, every report is public, and every vial carries a verifiable link to the raw data. For researchers who have wasted time and money on unreliable peptides, this level of transparency is not a luxury—it is a necessity.